A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PS / performance status

[Related PubMed/MEDLINE]
Total Number of Papers: 1946
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PS  (>> Co-occurring Abbreviation)
Long Form:   performance status
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma. ECOG, HRs, ICIs, LDH, OS, RCTs
2018 223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice. CI, HR, LD, OS
2018 A Chinese medicine warm compress (Wen Jing Zhi Tong Fang), combined with WHO 3-step analgesic ladder treatment for cancer pain relief: A comparative randomized trial. CMWC, QOL, VAS, WHO
2018 A Clinical Prognostic Score to Predict Survival of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy: A Retrospective Analysis. LDH, NSCLC, OS, PFS
2018 A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China. CHM, CI, CT, HCC, HR, IT
2018 A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. ABC, ET, mOS, mPFS
2018 A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer. AEs, NSCLC, ORR, OS, PEM, PFS, RT
2018 A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. HLA, PPV
2018 A Retrospective Analysis of the Clinical Outcomes of Leptomeningeal Metastasis in Patients with Solid Tumors. CSF, ECOG, LM
10  2018 A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. ECOG, NSCLC
11  2018 Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. AA, ADT, AEs, BMI, CVEs, ECOG, OS, PDN, PFS, PSA
12  2018 Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study. AOR, CI, HR, mCRC, OS, PFS
13  2018 Aidi Injection, a Traditional Chinese Medicine Injection, Could Be Used as an Adjuvant Drug to Improve Quality of Life of Cancer Patients Receiving Chemotherapy: A Propensity Score Matching Analysis. CI, OR, QOL
14  2018 Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. allo-HCT, FL, HLA, OS, PFS, TRM
15  2018 An Extended Hypofractionated Palliative Radiotherapy Regimen for Head and Neck Carcinomas. ---
16  2018 An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. aHCC, AIC, bNLR, CP, HCI, OS, pts
17  2018 An observational study of apatinib mesylate in treating advanced non-small cell lung cancer with unknown driving gene(s). AM, aNSCLC, DCR, ECOG, mPFS, ORR, PFS
18  2018 B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. AITL, beta2m, ENSs
19  2018 Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers. Cx, OS, PFS, PFU, R/MHNC
20  2018 Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review. CC
21  2018 Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. OS, RFS, UC
22  2018 Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? IDO, KYN, NSCLC, OS, PFS, Trp
23  2018 Can we avoid the toxicity of chemotherapy in elderly cancer patients? ---
24  2018 Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6. 5-FU, AOR, CI, RDI
25  2018 Clinical characteristics and treatment propensity in elderly patients aged over 80 years with colorectal cancer. CRC, OS
26  2018 Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer. DFS, FEV, NSCLC, OS, SMA
27  2018 Clinical outcome and prognostic analysis of meningeal carcinomatosis treated by intrathecal chemotherapy. ECOG, IC, MC, VEGF
28  2018 Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms. NSCLC, OS, VNR
29  2018 Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. GIST, LTRs
30  2018 Clinicopathological features of lung cancer in patients with rheumatoid arthritis. CTD, ECOG, LC, NSIP, RA, RA-ILD, UIP
31  2018 Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. CR, ECOG, SAEs, SWOG
32  2018 Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status. AMR, CE, ED-SCLC
33  2018 Definitive chemoradiotherapy with low-dose continuous 5-fluorouracil reduces hematological toxicity without compromising survival in esophageal squamous cell carcinoma patients. 5-FU, CRT, ESCC, LD5FU, OS
34  2018 Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery. GHS, HRQoL, MCID, SD, VAS
35  2018 Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups. EMR
36  2018 Diffusion-weighted MRI Is Superior to PET/CT in Predicting Survival of Patients Undergoing 90Y Radioembolization of Hepatic Metastases. DW, ECOG, FDG, RECIST
37  2018 Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. CBT, HSCT, LD, OS
38  2018 Effects of Serum Albumin, Calcium Levels, Cancer Stage and Performance Status on Weight Loss in Parathyroid Hormone-Related Peptide Positive or Negative Patients with Cancer. BMI, BW, PTHrP, WL
39  2018 Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. AEs, BCS, DFS, ECOG, HER2, LABC, VEGF
40  2018 Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. i.e., non-trial, NSCLC, PFS
41  2018 Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib. mRCC, OS, PZ, SU
42  2018 Efficacy of Gamma Knife Radiosurgery for Recurrent High-Grade Gliomas with Limited Tumor Volume. ECOG, GKR, OS, PFS
43  2018 Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status. SCLC
44  2018 Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status. IDS, NAC, W-TC
45  2018 EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC). ES, GH, NSCLC, PF, SumSC
46  2018 Factors improving the outcome of patients re-irradiated with intensity-modulated radiotherapy (IMRT) for relapse or new head and neck cancer developed in irradiated areas. IMRT, LRPFS, OS, PFS, re-RT
47  2018 Factors influencing treatment selection and 30-day mortality after chemotherapy for people with small-cell lung cancer: An analysis of national audit data. CI, OR, SCLC
48  2018 Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma. ECOG, EGFR, OS, PFS, SISH, TKI
49  2018 Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. OS, PFS
50  2018 Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while? NSCLC, OS, PTR, TNM
51  2018 Functional impairment attenuates the association between high serum phosphate and mortality in dialysis patients: a nationwide cohort study. MBD, PTH
52  2018 Geriatric assessment in clinical practice for patients with stage IV non-small-cell lung cancer: The Grup de Investigacio I Divulgacio Oncologica experience. GA, NSCLC
53  2018 Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. iRECIST
54  2018 Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. ECOG, I-O, ICPIs, NLR, NSCLC, PD, TILs, TTP
55  2018 Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06). CGA, La-NSCLC, OS, PFS
56  2018 Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). AML, CMML, ECOG, MDS, PFS, RBC
57  2018 Impact of the Charlson comorbidity index and prognostic nutritional index on prognosis in patients with early gastric cancer after endoscopic submucosal dissection. CCI, EGC, ESD, HR, OS, PNI
58  2018 Impact of total parenteral nutrition standardization led by pharmacist on quality in postoperative patients with colorectal cancer. TPN
59  2018 Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. HRQoL, MPM, PD, PTV
60  2018 Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients. ECOG, KPS
61  2018 Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. Co, HR, MV, NSCLC, PFS, TKI
62  2018 Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. AGC, CI, RDI
63  2018 Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy. HNSCC, OS, PFS
64  2018 Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort. ART, DLBCL, IQR, LDH, SSA, ULN
65  2018 Metastatic Gastric cancer: Real world scenario from a developing country. ECOG, OS, PFS
66  2018 Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres. mPRCC, OS, TA
67  2018 Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer. DCR, NSCLC, OS, PFS
68  2018 nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2. ECOG, NSCLC, TEAEs
69  2018 Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014). AC, EFS, LCNEC, NCI-E, NETs, OS, SCLC, TC
70  2018 No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer. AA, ARAT, ENZ, mCRPC, OS, PFS, PSA
71  2018 Nutrition support in hospitalized cancer patients with malnutrition in China. BMI, NRI, WL
72  2018 Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. MTD, SD
73  2018 Palliation of Brain Metastases: Analysis of Prognostic Factors Affecting Overall Survival. WBRT
74  2018 Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. AFP, BCLC, EHS, HCC, MVI, OS
75  2018 Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. HNSCC
76  2018 Performance of Current Thromboembolism Risk Assessment Tools in Patients With Gastric Cancer and Validity After First Treatment. CI, GC, HR, KRS, NLR, PLR, VTE
77  2018 Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. nab, PDAC
78  2018 Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. ---
79  2018 Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. CI, HR, NSCLC, PPS
80  2018 Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred? MMSE, MRI, NSCLC
81  2018 Predicting early death in older adults with cancer. CGA, CI, MNA, OR
82  2018 Predicting prognosis of short survival time after palliative whole-brain radiotherapy. BMs, GPA, LDH, MST, WBRT
83  2018 Prediction model for mortality in cancer patients with pneumonia: comparison with CURB-65 and PSI. ED, PSI
84  2018 Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. NSCLC, ORR, OS, PFS
85  2018 Prevalence of myofascial pain syndrome in patients with incurable cancer. MPS, RC, SC
86  2018 Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume PSA
87  2018 Prognostic Factors for Operated Gallbladder Cancer. DFS, OS, PNI
88  2018 Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy. CI, DC, HR, OS
89  2018 Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). OS, STS
90  2018 Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab. HNSCC, OS, PFS, REC
91  2018 Prognostic significance of inflammatory parameters and nutritional index in clinical stage IVB endometrial carcinomas. NLR, OS, PLR, PNI
92  2018 Prognostic significance of peripheral blood absolute monocyte count and lymphocyte to monocyte ratio in anaplastic large cell lymphoma. AMC, IPI, LMR, PIT, sALCL
93  2018 Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. HR, IPD, mCRC, PTR, RCTs
94  2018 Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma. EGFR, HR, OS, TKI, TTF-1
95  2018 Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial. BM, GTV, OD, OS, PCI, tGTV
96  2018 Pulmonary Dysfunction Function and Poor Nutritional Status are Risk Factors for Remote Infections Following Surgery for Colorectal Cancer. ASA, CONUT, mGPS, PNI, RI
97  2018 Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy. FACT-G, PRO, QOL, RBCT, TOI
98  2018 Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. BV, EV, HR, PFI, PFS
99  2018 Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. CIRS, LTS, ORR, OS, PDAC, PFS
100  2018 Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. ALK, CNS, CR, DS, EGFR, NSCLC, OS, PD, PFS, PR